Table 2.
Data of SBRT studies (January 2010 to October 2015) included in the meta‐analysis
| Author | Publication year | Research type | Research year range | Total patients | Operability | Male | Median age | Clinical stage | Pathological confirmation | Tumor size | Dose range | BED10 | Follow‐up (m) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (%) | (%) | IA | IB | IIA | IIB | (%) | (mm) | |||||||||
| Baba et al. 32 | 2010 | R | 2004–2008 | 124 | 32.4 | 67.7 | 77 | 87 | 37 | / | / | 91.9 | m27 | 44,48,52 | 92.4105.6119,6 | 26 (7–66) |
| Ricardi et al. 33 | 2010 | P | 2003–2007 | 62 | 9.7 | 83.9 | 74 | 43 | 19 | / | / | 64.5 | <50 | 45 | 124 | 28 (9–60.7) |
| Timmerman et al. 34 | 2010 | P | 2004–2006 | 55 | 0 | 38 | 72 | 44 | 11 | / | / | 100 | <50 | 54 | 151.2 | 34.3 (4.8–49.9) |
| Haasbeek et al. 35 | 2011 | R | 2003–2009 | 63 | 0 | 67 | 74 | 46 | 17 | / | / | 38.1 | Major < 70, 2 > 70 | 60 | 105 | 35 |
| Matsuo et al. 36 | 2011 | R | 1998–2007 | 101 | 36.6 | 73.3 | 77 | 33 | 40 | 28 | / | 100 | <= 40 | 48 | 105.6 | 31.4 |
| Nath et al. 37 | 2011 | R | 2007–2009 | 48 | 0 | 62% | 79 | / | / | / | / | / | / | 48 | 105.6 | 21 (10–41) |
| Chang et al. 38 | 2012 | R | 2005–2009 | 130 | 26.2 | 51.5 | 74 | 112 | 18 | / | / | / | <50 | 50 | 112.5 | 26 |
| Grills et al. 14 | 2012 | R | 1998–2010 | 483 | 13 | 52 | 74 | 304 | 159 | 10 | 5* | 64 | / | 20–64 | 132 | 19.6 (1.2–87.6) |
| Nuyttens et al. 39 | 2012 | R | 2006–2009 | 56 | 5.4 | / | 73 | / | / | / | / | / | m41 | 48 | >86.4 | 23 |
| Senthi et al. 40 | 2012 | R | 2003–2011 | 676 | 31 | 61 | 73 | / | / | / | / | / | / | 54–60 | 105–180 | 32.9 (14.9–50.9) |
| Shibamoto et al. 41 | 2012 | R | 2004–2008 | 180 | 33.3 | 68.3 | 77 | 128 | 52 | / | / | 100 | 12–50 | 44,48,52 | 92.4105.6119.6 | 36 |
| Takeda et al. 42 | 2012 | R | 2005–2011 | 115 | 27 | 78 | 78 | / | / | / | / | 100 | / | 40–50 | 72–100 | 21.2 (6–63.7) |
| Badiyan et al. 43 | 2013 | R | 2004–2009 | 120 | 0 | 52 | 74 | / | / | / | / | 80.8 | / | 54 | 151.2 | 29 |
| Griffioen et al. 44 | 2013 | R | 2003–2012 | 62 | / | 66 | 72 | / | / | / | / | / | 10–69,6–42 | 54–60 | >100 | 44 |
| Yoon et al. 45 | 2013 | R | 2007–2009 | 93 | / | 80.6 | 61 | / | / | / | / | / | 20 (10–60) | 30–60 | / | 25.6 |
| Haidar et al. 46 | 2014 | R | 2002–2012 | 55 | 21.3 | 63.5 | 78 | 37 | 18 | / | / | 58.2 | 25 (10–5) | 48–56 | 106.5–168 | 24.2 (1.9–64.6) |
| Lucas et al. 47 | 2014 | R | 2003–2011 | 81 | / | 48.1 | 81 | 67 | 14 | 3 | 1 | / | 23 (16–29) | 54 | 151.2 | 29.4 |
| Ricardi et al. 48 | 2014 | R | 2003–2011 | 196 | 7.7 | 74.5 | 75 | 155 | 41 | / | / | / | 24.8 (9‐50) | 45–60 | 100–151.2 | 30 |
| Davis et al. 49 | 2015 | R | 2004–2014 | 111 | 15.3 | 53.1 | 69 | / | / | / | / | / | 22.2 | 37.5,48 | 93.6105.6 | 17 (1–72) |
| Davis et al. 50 | 2015 | R | 2004–2013 | 723 | 48 | 48% | 76 | / | / | / | / | / | / | 54 (10–80) | 151.2 (20–240) | 12 (1–87) |
| Kelley et al. 51 | 2015 | R | 2010–2012 | 67 | 0 | 36 | 79 | 52 | IB‐III:15 | / | Volume < 20cc | 48 | 105.6 | 24.5 (2.4–50.3) | ||
| Kohutek et al. 52 | 2015 | R | 2006–2012 | 211 | / | 43.6 | 77 | / | / | / | / | 100 | / | >45 | < 100 (19.2%), > = 100 (80.8) | 25.2 (4.3–75.2) |
| Zehentmayr et al. 53 | 2015 | R | 2002–2010 | 54 | / | 66.7 | 71 | 40 | 14 | / | 37.5 (5–103) | 73.8–90 | / | 28.5 (2–108) | ||
| Schanne et al. 54 | 2015 | R | 2003–2011 | 567 | / | 70.7 | 72 | 297$ | 223 | 30 | / | / | 37.5(12–64) | 72 (43–180) | 18.8 | |
| I (not specified):16 | ||||||||||||||||
BED10: biological equivalent dose with α/β = 10, calculated based on the linear‐quadratic equation BED10 = nd [1 + d/(α/β)], where n and d represent the number of fractions and the dose per fraction, respectively. m, median; M, months; P, prospective; R, retrospective; SBRT, stereotactic body radiation therapy; /, not reported or obscure.